HRTX News and Press, Heron Therapeutics Inc. From 09/16/20

SAN DIEGO , Sept. 16, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced th...

SAN DIEGO , Sept. 11, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that&#x...

Heron Therapeutics (NASDAQ: HRTX ) announces  a successful Type A meeting with the FDA in which alignment was reached to resubmit the New Drug Application or NDA for HTX-011 in Q4. More news on: Heron Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ......

SAN DIEGO , Sept. 8, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced a s...

Shares of Heron Therapeutics (NASDAQ: HRTX) , a small-cap drugmaker, gained 10.7% over the course of July, according to data provided by S&P Global Market Intelligence . The biotech's shares seemingly benefited from a wave of bargain buying last month following the company's sharp pullba...

Quick Take PainReform ( PRFX ) intends to raise $23 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing a reformulated pain relief medication for post-operative pain reduction. PRFX management has performed well...

SAN DIEGO , Aug. 5, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best–in-class treatments to address some of the most important unmet patient needs, today announc...

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Heron Therapeutics' (NASDAQ: HRTX ) Zynrelef (formerly HTX-011), a fixed-dose combination of local anesthetic bupivacaine and nonsteroidal anti-inflammatory med meloxicam, for the ...

SAN DIEGO , July 24, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the...

Evercore ISI has added a healthy 19 stocks in a fresh resumption of its best SMID "core" ideas this month - the research team's very best small and mid-cap stocks. More news on: Cheniere Energy, Inc., WPX Energy, Inc., Chart Industries, Inc., Notable Calls, Healthcare stocks news, Energy s...